[go: up one dir, main page]

HN2007000536A - Formas cristalinas - Google Patents

Formas cristalinas

Info

Publication number
HN2007000536A
HN2007000536A HN2007000536A HN2007000536A HN2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A
Authority
HN
Honduras
Prior art keywords
crystal forms
tetrafluofenoxi
tercbutilfenil
oxopentanoico
alamini
Prior art date
Application number
HN2007000536A
Other languages
English (en)
Inventor
Dimmock Stuart
Hagen Eric
Hanko Jason
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2007000536A publication Critical patent/HN2007000536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMAS CRISTALINAS DEL ACIDO (3S)- {N-(N -(2-TERCBUTILFENIL) OXAMIL) ALAMINI} AMINO-5-(2, 3, 5, 6-TETRAFLUOFENOXI)-4-OXOPENTANOICO.
HN2007000536A 2006-12-06 2007-12-04 Formas cristalinas HN2007000536A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
HN2007000536A true HN2007000536A (es) 2011-01-17

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2007000536A HN2007000536A (es) 2006-12-06 2007-12-04 Formas cristalinas

Country Status (22)

Country Link
US (1) US7692038B2 (es)
EP (1) EP2091910B1 (es)
JP (1) JP5495787B2 (es)
KR (1) KR101125932B1 (es)
CN (3) CN101573328B (es)
AR (1) AR064809A1 (es)
AU (1) AU2007330478B2 (es)
CA (1) CA2669849C (es)
CL (1) CL2007003491A1 (es)
DK (1) DK2091910T3 (es)
ES (1) ES2524021T3 (es)
HN (1) HN2007000536A (es)
IL (1) IL198732A (es)
MX (1) MX2009006055A (es)
NO (1) NO338908B1 (es)
PA (1) PA8759501A1 (es)
PE (1) PE20081251A1 (es)
PL (1) PL2091910T3 (es)
PT (1) PT2091910E (es)
TW (1) TWI345466B (es)
UY (1) UY30758A1 (es)
WO (1) WO2008068615A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5745283B2 (ja) * 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
EA036325B1 (ru) * 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
SG11201609256SA (en) 2014-05-12 2016-12-29 Conatus Pharmaceuticals Inc Treatment of the complications of chronic liver disease with caspase inhibitors
SG11201700958YA (en) * 2014-09-08 2017-03-30 Pfizer Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
EP3250562B1 (en) 2015-01-30 2024-11-27 Biomed Valley Discoveries, Inc. Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US20190022043A1 (en) 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
WO2018065902A1 (en) 2016-10-05 2018-04-12 Novartis Ag Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
TWI764977B (zh) 2017-01-23 2022-05-21 大陸商正大天晴藥業集團股份有限公司 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
CN110446706B (zh) * 2017-03-30 2023-05-16 默克专利股份公司 (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的晶型
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
TW202100506A (zh) 2019-03-07 2021-01-01 美商柯納特斯製藥公司 半胱天冬酶(caspase)抑制劑及其使用方法
JP2022546861A (ja) * 2019-09-10 2022-11-09 ミラティ セラピューティクス， インコーポレイテッド マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
CN115768432A (zh) 2020-04-23 2023-03-07 南方研究院 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
CA3186696A1 (en) * 2020-07-23 2022-01-27 Mark J. Suto Polymorphs of 5-aza-4'-thio-2-deoxycytidine
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526171B1 (en) * 1991-07-30 1997-03-05 Ajinomoto Co., Inc. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
EP0625504B1 (de) * 1993-05-12 1997-08-27 HEUMANN PHARMA GmbH Stabile und kristalline Form von Bezafibrat
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
CN1312121C (zh) * 2001-12-11 2007-04-25 杏林制药株式会社 取代苯基丙酸衍生物的新的稳定结晶及其制造方法
KR20080017094A (ko) * 2005-07-11 2008-02-25 화이자 리미티드 간 섬유증을 치료하기 위한 항-ＭＡｄＣＡＭ 항체 및항섬유성 캐스파아제 억제제의 신규한 조합물

Also Published As

Publication number Publication date
IL198732A (en) 2014-02-27
TWI345466B (en) 2011-07-21
CA2669849C (en) 2012-01-31
AU2007330478A1 (en) 2008-06-12
PA8759501A1 (es) 2009-04-23
AU2007330478B2 (en) 2011-09-08
US7692038B2 (en) 2010-04-06
CN103951583B (zh) 2016-01-06
UY30758A1 (es) 2008-07-31
WO2008068615A8 (en) 2009-05-28
CN103951583A (zh) 2014-07-30
JP2010511689A (ja) 2010-04-15
CN103923169B (zh) 2017-05-24
TW200833319A (en) 2008-08-16
KR20090080113A (ko) 2009-07-23
EP2091910B1 (en) 2014-08-20
HK1200440A1 (zh) 2015-08-07
PT2091910E (pt) 2014-11-18
IL198732A0 (en) 2010-02-17
CN103923169A (zh) 2014-07-16
CN101573328B (zh) 2014-04-02
PL2091910T3 (pl) 2015-02-27
NO20091892L (no) 2009-06-17
NO338908B1 (no) 2016-10-31
PE20081251A1 (es) 2008-09-17
CL2007003491A1 (es) 2008-06-20
MX2009006055A (es) 2009-06-16
ES2524021T3 (es) 2014-12-03
CA2669849A1 (en) 2008-06-12
HK1199885A1 (zh) 2015-07-24
US20080249031A1 (en) 2008-10-09
EP2091910A1 (en) 2009-08-26
DK2091910T3 (en) 2014-12-01
HK1138567A1 (en) 2010-08-27
CN101573328A (zh) 2009-11-04
JP5495787B2 (ja) 2014-05-21
KR101125932B1 (ko) 2012-03-22
WO2008068615A1 (en) 2008-06-12
AR064809A1 (es) 2009-04-29

Similar Documents

Publication Publication Date Title
HN2007000536A (es) Formas cristalinas
GT200600315A (es) Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CR10157A (es) Compuestos químicos
EA200801959A1 (ru) Высокоразветвленный полипропилен
CR9369A (es) Compuestos de peridil acido acetico
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
CR11161A (es) Procesos para la produccion de pirazoles
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
UA107791C2 (en) Pesticidal compositions
CO6311002A2 (es) Agentes fijadores y epitopos wise
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
TW200745028A (en) Novel sulphonylpyrroles
ECSP10010192A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
UA107592C2 (uk) Композиція для боротьби з захворюваннями рослин і її застосування
TW200745027A (en) Novel sulphonylpyrroles
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
ECSP10010491A (es) Composiciones fungicidas con 3'-bromo-2,3,4,6'-tetrametoxi-2',6-dimetilbenzofenona
CY1116596T1 (el) Αλατα ισοφωσφοραμιδικης μουσταρδας και αναλογα αυτων
GT200700105A (es) Inhibidor del factor xa
TW200640886A (en) Crystalline forms of linezolid intermediate
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina